MCID: MLT019
MIFTS: 82

Multiple Myeloma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Multiple Myeloma

MalaCards integrated aliases for Multiple Myeloma:

Name: Multiple Myeloma 54 38 12 50 24 25 56 71 29 13 41 42 14 69
Plasma Cell Myeloma 12 50 56 52
Medullary Plasmacytoma 25 56 69
Plasma Cell Dyscrasia 50 25 69
Myelomatosis 50 25 56
Primary Systemic Amyloidosis 56 69
Primary Amyloidosis 56 69
Kahler's Disease 25 56
Kahler Disease 50 25
Immunoglobulin Deposition Disease 69
Systemic Al Amyloidosis 56
Light-Chain Amyloidosis 56
Kahler-Bozzolo Disease 25
Plasma Cell Neoplasm 69
Plasma Cell Myelomas 25
Myeloma - Multiple 50
Al Amyloidosis 56
Mm 71

Characteristics:

Orphanet epidemiological data:

56
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
primary systemic amyloidosis
Inheritance: Not applicable;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

54
Inheritance:
somatic mutation


HPO:

32
multiple myeloma:
Inheritance somatic mutation autosomal recessive inheritance


Classifications:



Summaries for Multiple Myeloma

NIH Rare Diseases : 50 multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. when present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. the exact underlying cause of multiple myeloma is currently unknown. factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, african american race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (mgus). treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting. last updated: 3/12/2016

MalaCards based summary : Multiple Myeloma, also known as plasma cell myeloma, is related to drug-induced hepatitis and hepatocellular carcinoma, and has symptoms including splenomegaly, anemia and vertebral compression fractures. An important gene associated with Multiple Myeloma is LIG4 (DNA Ligase 4), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Aredia and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are behavior/neurological and growth/size/body region

UniProtKB/Swiss-Prot : 71 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

MedlinePlus : 41 multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. these cells are part of your immune system, which helps protect the body from germs and other harmful substances. in time, myeloma cells collect in the bone marrow and in the solid parts of bones. no one knows the exact causes of multiple myeloma, but it is more common in older people and african americans. it can run in families. common symptoms may include bone pain, often in the back or ribs broken bones weakness or fatigue weight loss frequent infections and fevers feeling very thirsty frequent urination doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. your treatment depends on how advanced the disease is and whether you have symptoms. if you have no symptoms, you may not need treatment right away. if you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

Genetics Home Reference : 25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.

OMIM : 54
Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500)

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

Wikipedia : 72 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Related Diseases for Multiple Myeloma

Diseases in the Multiple Myeloma family:

Igh-Related Multiple Myeloma

Diseases related to Multiple Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 455)
id Related Disease Score Top Affiliating Genes
1 drug-induced hepatitis 30.1 CCND1 CDK4 IRF4 MYC
2 hepatocellular carcinoma 29.4 CCND1 CDK4 IL6 IL6R MCL1 MYC
3 igh-related multiple myeloma 11.9
4 plasma cell leukemia 11.6
5 light chain deposition disease 11.5
6 monoclonal gammopathy of uncertain significance 11.4
7 hematopoietic stem cell transplantation 11.2
8 epidermolysis bullosa acquisita 11.2
9 hypoaldosteronism 11.2
10 smoldering myeloma 11.2
11 lymphoplasmacytic lymphoma 11.2
12 primary malignant melanoma of the conjunctiva 11.0 IL6 IRF4 MYC
13 acute allergic sanguinous otitis media 11.0 CCND1 IL6 IL6R MYC
14 keloids 10.9 DKK1 IL6 IL6R
15 gingival recession 10.9 CCND1 IRF4 MCL1 MYC
16 plasmacytoma 10.9
17 hypogonadotropism 10.9 IL6 MAF NCAM1 NSD2
18 mesomelia-synostoses syndrome 10.9
19 microphthalmia, isolated 6 10.9
20 mitral valve prolapse, myxomatous 1 10.9
21 plexosarcoma 10.8 CCND1 FGFR3 IRF4 MAF NCAM1
22 fetal thalidomide syndrome 10.8
23 dyserythropoietic anemia, congenital, type iii 10.8
24 medial medullary syndrome 10.8
25 miyoshi muscular dystrophy 1 10.8
26 gallbladder cancer 10.8 CCND1 IL6 MYC
27 x-linked lissencephaly with abnormal genitalia 10.8
28 megalocornea 1, x-linked 10.8
29 choroid disease 10.8
30 mitral valve prolapse 2 10.8
31 microcoria, congenital 10.8
32 sessile serrated polyposis cancer syndrome 10.8
33 urethra adenocarcinoma 10.8 CCND1 MYC NCAM1
34 hemoglobinemia 10.8 CCND1 MYC
35 melanoma metastasis 10.7 CCND1 CD19 IRF4
36 extramedullary plasmacytoma 10.7
37 solitary plasmacytoma of chest wall 10.7 CCND1 IL6
38 unilateral retinoblastoma 10.6 CCND1 CDK4 MYC
39 esophagus lymphoma 10.6 CCND1 CDK4 FGFR3 IL6 MYC
40 pharynx cancer 10.6 CCND1 CDK4 MYC
41 smoking as a quantitative trait locus 1 10.6 CCND1 CD19 IRF4 MCL1 MYC
42 cataract 40, x-linked 10.6
43 endomyocardial fibrosis 10.6
44 cataract 2, multiple types 10.6
45 cataract 47, juvenile, with microcornea 10.6
46 glaucoma 1, open angle, p 10.6
47 cataract microcornea syndrome 10.6
48 isolated congenital megalocornea 10.6
49 bronchiolo-alveolar adenocarcinoma 10.6
50 hypereosinophilic syndrome 10.6

Graphical network of the top 20 diseases related to Multiple Myeloma:



Diseases related to Multiple Myeloma

Symptoms & Phenotypes for Multiple Myeloma

Symptoms via clinical synopsis from OMIM:

54

Neoplasia:
multiple myeloma

Laboratory- Abnormalities:
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)
paraproteinemia


Clinical features from OMIM:

254500

Human phenotypes related to Multiple Myeloma:

56 32 (show top 50) (show all 80)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 56 32 very rare (1%) Very rare (<4-1%) HP:0001744
2 anemia 56 32 frequent (33%) Frequent (79-30%) HP:0001903
3 vertebral compression fractures 56 32 occasional (7.5%) Occasional (29-5%) HP:0002953
4 fatigue 56 32 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0012378
5 osteopenia 56 32 hallmark (90%) Very frequent (99-80%) HP:0000938
6 spinal cord compression 56 32 occasional (7.5%) Occasional (29-5%) HP:0002176
7 bone pain 56 32 frequent (33%) Frequent (79-30%) HP:0002653
8 lymphadenopathy 56 32 very rare (1%) Very rare (<4-1%),Frequent (79-30%) HP:0002716
9 hypercalcemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003072
10 nephrotic syndrome 56 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000100
11 tall stature 56 32 occasional (7.5%) Occasional (29-5%) HP:0000098
12 weight loss 56 32 occasional (7.5%) Occasional (29-5%) HP:0001824
13 generalized muscle weakness 56 32 frequent (33%) Frequent (79-30%) HP:0003324
14 nephropathy 56 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000112
15 pleural effusion 56 32 very rare (1%) Very rare (<4-1%),Occasional (29-5%) HP:0002202
16 elevated serum creatinine 56 32 frequent (33%) Frequent (79-30%) HP:0003259
17 paresthesia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003401
18 multiple myeloma 56 32 Frequent (79-30%) HP:0006775
19 pathologic fracture 56 32 hallmark (90%) Very frequent (99-80%) HP:0002756
20 decreased antibody level in blood 56 32 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0004313
21 abnormality of the bladder 56 32 occasional (7.5%) Occasional (29-5%) HP:0000014
22 acute kidney injury 56 32 frequent (33%) Frequent (79-30%) HP:0001919
23 functional abnormality of the gastrointestinal tract 56 32 occasional (7.5%) Occasional (29-5%) HP:0012719
24 increased iga level 56 32 occasional (7.5%) Occasional (29-5%) HP:0003261
25 increased igg level 56 32 frequent (33%) Frequent (79-30%) HP:0003237
26 hyperproteinemia 56 32 frequent (33%) Frequent (79-30%) HP:0002152
27 abnormality of vitamin b12 metabolism 56 32 occasional (7.5%) Occasional (29-5%) HP:0004341
28 macroglossia 56 Occasional (29-5%)
29 hepatomegaly 56 Frequent (79-30%)
30 hematuria 56 Occasional (29-5%)
31 proteinuria 56 Frequent (79-30%)
32 hypertrophic cardiomyopathy 56 Very frequent (99-80%)
33 renal insufficiency 56 Frequent (79-30%)
34 constipation 56 Frequent (79-30%)
35 hypertension 56 Occasional (29-5%)
36 dyspnea 56 Frequent (79-30%)
37 purpura 56 Occasional (29-5%)
38 arrhythmia 56 Frequent (79-30%)
39 malabsorption 56 Occasional (29-5%)
40 congestive heart failure 56 Frequent (79-30%)
41 bradycardia 56 Occasional (29-5%)
42 osteoarthritis 56 Occasional (29-5%)
43 arthropathy 56 Frequent (79-30%)
44 gastrointestinal dysmotility 56 Occasional (29-5%)
45 goiter 56 Occasional (29-5%)
46 aortic root dilatation 56 Occasional (29-5%)
47 polyneuropathy 56 Occasional (29-5%)
48 intermittent claudication 56 Occasional (29-5%)
49 enlarged kidneys 56 Frequent (79-30%)
50 asplenia 56 Occasional (29-5%)

MGI Mouse Phenotypes related to Multiple Myeloma:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 IL6R LIG4 MAF MYC NBEA NCAM1
2 growth/size/body region MP:0005378 10.25 DKK1 FGFR3 IL6 IL6R LIG4 MAF
3 cellular MP:0005384 10.24 DKK1 FGFR3 IL6 IL6R LIG4 MCL1
4 homeostasis/metabolism MP:0005376 10.18 MYC NBEA CCND1 CD19 CDK4 CRBN
5 endocrine/exocrine gland MP:0005379 10.11 CCND1 CDK4 CRBN IL6 IL6R LIG4
6 immune system MP:0005387 10.11 CCND1 CD19 CDK4 FGFR3 IL6 IL6R
7 digestive/alimentary MP:0005381 10.08 CCND1 CD19 CDK4 FGFR3 IL6 LIG4
8 mortality/aging MP:0010768 10 CCND1 CD19 CDK4 DKK1 FGFR3 IL6
9 integument MP:0010771 9.97 CDK4 FGFR3 IL6 MAF MCL1 MYC
10 liver/biliary system MP:0005370 9.8 IL6R LIG4 MYC CD19 CDK4 CRBN
11 neoplasm MP:0002006 9.61 CCND1 CD19 CDK4 FGFR3 IL6 IL6R
12 nervous system MP:0003631 9.4 MAF MYC NBEA NCAM1 CCND1 CD19

Drugs & Therapeutics for Multiple Myeloma

FDA approved drugs:

(show all 17)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Aredia 17 46 PAMIDRONATE DISODIUM Chiron August 1996
2
Busulfex 17 46 BUSULFAN Orphan Medical February 1999
3
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza June 1999
4
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
5
Farydak 17 46 PANOBINOSTAT LACTATE Novartis February 2015
6
Kyprolis 17 46 CARFILZOMIB Onyx Pharmaceuticals July 2012
7
Mozobil 17 46 PLERIXAFOR Genzyme December 2008
8
Pomalyst 17 46 POMALIDOMIDE Celgene February 2013
9
Revlimid 17 46 LENALIDOMIDE Celgene June 2013
10
Sprycel 17 46 DASATINIB Bristol-Myers Squibb June 2006
11
Subsys 17 FENTANYL Insys Therapeutics January of 2012
12
Velcade 17 46 BORTEZOMIB Millennium Pharmaceuticals May 2003
13
Xgeva 17 46 DENOSUMAB Amgen June 2013/ November 2010
14
Zoladex 17 46 GOSERELIN ACETATE AstraZeneca January 1996
15
Zometa 17 46 ZOLEDRONIC ACID Novartis August 2001/ February 2002
16
Adempas 17 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
17
Vibativ 17 * TELAVANCIN * TELAVANCIN HYDROCHLORIDE Theravance June 2013

Drugs for Multiple Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 684)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
2
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
6
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Panobinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 404950-80-7 6918837
8
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
9
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
10
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
11
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
14
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
15
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
16
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
17
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
18
Phentolamine Approved Phase 4 50-60-2 5775
19
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
20
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
21 Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
22 Ixazomib Approved Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
25
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
26
Pirarubicin Investigational Phase 4 72496-41-4
27 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
36 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2371)

id Name Status NCT ID Phase Drugs
1 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
2 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
3 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
4 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
5 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
6 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 4 panobinostat;bortezomib;dexamethasone
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
8 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
9 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
10 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
11 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
12 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4 No intervention
13 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
14 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4 bortezomib
15 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4 bortezomib
16 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4 bortezomib
17 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4 Bortezomib;Melphalan;Prednisone
18 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
19 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
20 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4 No intervention
21 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
22 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4 bortezomib
23 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4 Bortezomib
24 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4 bortezomib
25 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
26 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
27 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
28 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
29 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
30 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4 piperacillin-tazobactam;glycopeptide
31 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
32 Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation Completed NCT01738373 Phase 4 Plerixafor
33 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
34 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Recruiting NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
35 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
36 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
37 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
38 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
39 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Not yet recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
40 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE MM-6) Not yet recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
41 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
42 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
43 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
44 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
45 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
46 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
47 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
48 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
49 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
50 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone

Search NIH Clinical Center for Multiple Myeloma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Myeloma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: multiple myeloma

Genetic Tests for Multiple Myeloma

Genetic tests related to Multiple Myeloma:

id Genetic test Affiliating Genes
1 Multiple Myeloma 29 24 LIG4

Anatomical Context for Multiple Myeloma

MalaCards organs/tissues related to Multiple Myeloma:

39
Bone, Bone Marrow, T Cells, B Cells, Testes, Kidney, Myeloid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Myeloma:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Multiple Myeloma

Articles related to Multiple Myeloma:

(show top 50) (show all 3526)
id Title Authors Year
1
Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma: A phase 1 study in Japan. ( 28092421 )
2017
2
Paraneoplastic acute disseminated encephalomyelitis associated with multiple myeloma. ( 28427695 )
2017
3
EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma. ( 28351297 )
2017
4
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. ( 28420429 )
2017
5
IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )
2017
6
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. ( 28096095 )
2017
7
Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells. ( 28653881 )
2017
8
Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma. ( 28945732 )
2017
9
Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. ( 28945825 )
2017
10
Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity. ( 27454822 )
2017
11
Utilizing next-generation sequencing in the management of multiple myeloma. ( 28524737 )
2017
12
Risk of vertebral compression fractures in multiple myeloma patients: A finite-element study. ( 28079810 )
2017
13
CUL4A as a marker and potential therapeutic target in multiple myeloma. ( 28677427 )
2017
14
Genetic deletion of sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. ( 28529307 )
2017
15
Network-based analysis of the molecular mechanisms of multiple myeloma and monoclonal gammopathy of undetermined significance. ( 28943924 )
2017
16
Dermoscopy of cutaneous involvement by multiple myeloma. ( 28087038 )
2017
17
Two different causes in a patient with distal symmetric axonal polyneuropathy: Churg-Strauss syndrome and multiple myeloma, coincidental or associated with each other? ( 28332041 )
2017
18
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. ( 28337527 )
2017
19
The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. ( 28381753 )
2017
20
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study. ( 28535102 )
2017
21
18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. ( 28822997 )
2017
22
G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. ( 28509594 )
2017
23
Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. ( 28154173 )
2017
24
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. ( 28082445 )
2017
25
Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. ( 28920142 )
2017
26
Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. ( 28085010 )
2017
27
bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients. ( 28373444 )
2017
28
Mechanisms of bone destruction in multiple myeloma. ( 28940410 )
2017
29
Current Strategies for the Immunotherapy of Multiple Myeloma. ( 28090624 )
2017
30
New Treatment Options for the Management of Multiple Myeloma. ( 28515251 )
2017
31
Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. ( 28068938 )
2017
32
Priapism with penile gangrene: An unusual presentation of multiple myeloma. ( 28717280 )
2017
33
Multiple myeloma presenting with bilateral ankle pain (microangiopathy) and complicated by streptococcal meningitis and Pneumocystis carinii pneumonia. ( 28174184 )
2017
34
Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. ( 28385149 )
2017
35
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. ( 28669490 )
2017
36
IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts. ( 28057743 )
2017
37
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. ( 28151428 )
2017
38
hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. ( 28000886 )
2017
39
Multiple myeloma associated intestinal amyloidosis: intestinal pseudo-obstruction falsely considered as an ascites. ( 28875827 )
2017
40
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. ( 28513828 )
2017
41
Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture. ( 28512409 )
2017
42
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. ( 28522572 )
2017
43
Immunoglobulin A Lambda Multiple Myeloma in a Patient with HIV: An Unusual Cause of Massive Ascites. ( 28512393 )
2017
44
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. ( 28369102 )
2017
45
Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience. ( 28091419 )
2017
46
C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. ( 28356669 )
2017
47
Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. ( 28079685 )
2017
48
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. ( 27909306 )
2017
49
A compound chimeric antigen receptor strategy for targeting multiple myeloma. ( 28951562 )
2017
50
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. ( 27677741 )
2017

Variations for Multiple Myeloma

ClinVar genetic disease variations for Multiple Myeloma:

6 (show top 50) (show all 132)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
4 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
5 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
6 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
7 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
8 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
9 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
10 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
11 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
13 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
14 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
15 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
16 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
17 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
18 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
19 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
20 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
21 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
22 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
23 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
24 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
25 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
26 FGFR3 NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu) single nucleotide variant Pathogenic/Likely pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
27 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
28 FGFR3 FGFR3, FGFR3/IGH FUSION undetermined variant Pathogenic
29 CDK4 NM_000075.3(CDK4): c.70C> T (p.Arg24Cys) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs11547328 GRCh37 Chromosome 12, 58145431: 58145431
30 CDK4 NM_000075.3(CDK4): c.71G> A (p.Arg24His) single nucleotide variant Likely pathogenic,risk factor rs104894340 GRCh37 Chromosome 12, 58145430: 58145430
31 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
32 MYD88 NM_001172567.1(MYD88): c.818T> C (p.Leu273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
33 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
34 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic/Likely pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
35 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
36 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
37 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
38 PTPN11 NM_002834.4(PTPN11): c.1508G> T (p.Gly503Val) single nucleotide variant Likely pathogenic rs397507546 GRCh37 Chromosome 12, 112926888: 112926888
39 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
40 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
41 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
42 BRAF NM_004333.4(BRAF): c.1741A> C (p.Asn581His) single nucleotide variant Likely pathogenic rs180177040 GRCh37 Chromosome 7, 140453987: 140453987
43 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
44 BRAF NM_004333.4(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
45 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
46 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
47 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
48 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
49 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
50 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285

Copy number variations for Multiple Myeloma from CNVD:

7 (show top 50) (show all 302)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
7 17467 1 142902432 245422432 Gain Multiple myeloma
8 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
9 20611 1 153300000 154800000 Gain EST1B Multiple myeloma
10 20700 1 1536308 6536308 Loss Multiple myeloma
11 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
12 20849 1 154800000 158800000 Gain CAPON Multiple myeloma
13 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
14 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
15 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
16 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
17 29497 1 23265113 23869113 Loss Multiple myeloma
18 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
19 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
20 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
21 31749 1 30500000 184000000 Gain Multiple myeloma
22 33943 1 50669458 53683458 Loss Multiple myeloma
23 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
24 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
25 36791 1 80821425 83677425 Loss Multiple myeloma
26 36969 1 84171854 96213854 Loss Multiple myeloma
27 37035 1 84700000 88100000 Gain Multiple myeloma
28 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
29 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
30 37525 10 30762871 30790767 Gain EST Multiple myeloma
31 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
32 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
33 41379 10 17300000 22600000 Gain and amplificati on Multiple myeloma
34 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
35 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
36 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
37 48574 11 100828925 102320925 Loss KIAA1377 Multiple myeloma
38 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
39 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
40 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
41 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
42 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
43 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
44 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
45 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
46 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
47 48584 11 100828925 102320925 Loss PORIMIN Multiple myeloma
48 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
49 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma
50 49668 11 110000000 112800000 Gain POU2AF1 Multiple myeloma

Expression for Multiple Myeloma

Search GEO for disease gene expression data for Multiple Myeloma.

Pathways for Multiple Myeloma

Pathways related to Multiple Myeloma according to GeneCards Suite gene sharing:

(show all 37)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 BST2 C1orf35 CCND1 CD19 FGFR3 IL6
2
Show member pathways
13.17 BST2 CCND1 FGFR3 IL6 IL6R IRF4
3 12.61 CCND1 CDK4 FGFR3 IL6 MYC
4
Show member pathways
12.5 CCND1 CDK4 FGFR3 IL6 IL6R MYC
5 12.37 CCND1 CDK4 DKK1 MYC
6 12.36 CCND1 CDK4 IL6 MYC
7
Show member pathways
12.34 IL6 IL6R IRF4 MAF MCL1 MYC
8 12.17 IL6 MAF MYC NSD2
9
Show member pathways
12.14 CCND1 CDK4 FGFR3 IL6R MYC
10 12.1 CCND1 IL6 IL6R MYC
11 12.09 CCND1 CD19 CDK4 FGFR3 IL6 IL6R
12 11.98 DKK1 IL6 MYC NCAM1
13
Show member pathways
11.89 CCND1 IL6 IL6R MCL1 MYC
14 11.87 CCND1 CDK4 IL6 MYC
15 11.84 CCND1 CDK4 IL6
16 11.83 CD19 IL6 IL6R
17 11.82 CD19 IL6 NCAM1
18
Show member pathways
11.8 IL6 IL6R IRF4
19 11.76 CCND1 CDK4 MYC
20 11.75 CCND1 CDK4 MYC
21 11.71 CCND1 DKK1 MYC
22 11.7 CCND1 MAF MYC
23
Show member pathways
11.69 IL6 IL6R MCL1 MYC
24
Show member pathways
11.68 CDK4 IRF4 MAF
25 11.61 CD19 IL6 IRF4 NCAM1
26 11.58 CCND1 DKK1 MYC
27 11.53 CCND1 CDK4 FGFR3 MYC
28 11.51 CCND1 CDK4 IL6
29 11.48 CCND1 IL6 MCL1
30 11.43 DKK1 IL6 IL6R
31 11.41 CCND1 DKK1 MYC
32 11.38 CCND1 CDK4 MYC
33 11.28 CCND1 CDK4 MYC
34 11.23 CCND1 IL6 MYC
35 11.16 CCND1 IL6 IL6R MYC
36 11.16 CCND1 IL6 IL6R IRF4 MCL1 MYC
37 11.07 CCND1 CDK4 MYC

GO Terms for Multiple Myeloma

Cellular components related to Multiple Myeloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 BST2 FGFR3 IL6R MICA NCAM1
2 interleukin-6 receptor complex GO:0005896 8.62 IL6 IL6R

Biological processes related to Multiple Myeloma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 G1/S transition of mitotic cell cycle GO:0000082 9.65 CCND1 CDK4 MYC
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 FGFR3 IL6 IL6R
3 response to cytokine GO:0034097 9.5 IL6 IL6R MCL1
4 positive regulation of chemokine production GO:0032722 9.49 IL6 IL6R
5 positive regulation of leukocyte chemotaxis GO:0002690 9.46 IL6 IL6R
6 interleukin-6-mediated signaling pathway GO:0070102 9.43 IL6 IL6R
7 positive regulation of fibroblast proliferation GO:0048146 9.43 CDK4 LIG4 MYC
8 positive regulation of cell proliferation GO:0008284 9.43 CCND1 CDK4 FGFR3 IL6 IL6R MYC
9 positive regulation of translation GO:0045727 9.37 CDK4 IL6
10 T-helper 17 cell lineage commitment GO:0072540 9.16 IL6 IRF4
11 hepatic immune response GO:0002384 8.62 IL6 IL6R

Molecular functions related to Multiple Myeloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 BST2 C1orf35 CCND1 CD19 CDK4 CRBN
2 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.16 CCND1 CDK4
3 interleukin-6 receptor binding GO:0005138 8.96 IL6 IL6R

Sources for Multiple Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....